TTK Healthcare bonus issue of NCRPS: 5:1 ratio approved under Scheme
Board clears Scheme of Arrangement to issue 5 Non-Convertible Redeemable Preference Shares of Rs.100 each as bonus for every 1 equity share, subject to approvals.
Key takeaways
- 5 NCRPS of Rs.100/- each will be issued by way of bonus for every 1 equity share of Rs.10/- each held as on the Record Date.
- Total 7,06,51,665 NCRPS of Rs.100/- each will be issued, amounting to Rs 706.52 cr.
- Rate of dividend on the NCRPS is 9.5% per annum with a tenure of 15 months from allotment.
- The NCRPS are proposed to be listed on BSE Limited and the National Stock Exchange of India Limited.
- Record Date for determining eligible shareholders is referred to in the Scheme but not specified in the filing.
Key dates and terms
- Action
- Bonus issue
- Terms
- 5 NCRPS of Rs.100/- each for every 1 equity share of Rs.10/- each
- Record date
- Not announced yet
- Total 7,06,51,665 NCRPS aggregating to Rs 706.52 cr
- Dividend rate on NCRPS is 9.5% per annum for 15 months
TTK Healthcare Limited’s board has approved a Scheme of Arrangement with its equity shareholders for a bonus issue of Non-Convertible Redeemable Preference Shares (NCRPS), according to the outcome letter dated November 20, 2026.
The Scheme of Arrangement under Section 230 of the Companies Act, 2013 provides for issuing and allotting NCRPS by way of bonus to existing equity shareholders, subject to statutory, regulatory and shareholder approvals.
Key terms
- Type of instrument: Non-Convertible Redeemable Preference Shares ("NCRPS").
- Type of issuance: Bonus Issue (as per Annexure-A).
- Bonus ratio: 5 NCRPS of Rs.100/- each fully paid up by way of bonus for every 1 equity share of Rs.10/- each fully paid up held as on the Record Date (as defined under the Scheme).
- Face value: Rs.100/- per NCRPS.
- Issue price: Rs.100/- per NCRPS (Face value).
- Total number of securities: 7,06,51,665 of NCRPS of Rs.100/- each.
- Issue size / amount: 7,06,51,665 NCRPS amounting to Rs 706.52 cr [Rs 706.52 cr].
- Rate of dividend: 9.5% per annum.
- Tenure: 15 (Fifteen) months from the date of allotment.
- Redemption / maturity: The NCRPS shall be redeemed at par at the end of the tenure or at any time prior to such date at the option of the Board of Directors of the Company.
- Listing: Proposed to be listed on BSE Limited and the National Stock Exchange of India Limited, where the equity shares are currently listed.
- Utilisation of reserves: The issuance of NCRPS by way of bonus is proposed under the Scheme by utilizing general reserves and / or retained earnings of the Company.
- Estimated reserve utilisation: Assuming the existing number of equity shares, an amount of around Rs 706.52 cr will be utilized from general reserves and / or retained earnings of the Company for issuance of bonus NCRPS, under the Scheme.
The filing in Annexure-A states that as on September 30, 2026 (Limited Reviewed), general reserves stood at Rs 78.48 cr and retained earnings at Rs 1,222.86 cr. These figures are based on the Limited Reviewed Financial Results by the Statutory Auditors of the Company for the quarter and half-year ended September 30, 2026.
Record date and eligibility
The bonus ratio is defined with reference to a Record Date, but the specific Record Date has not been stated in the filing. The document repeatedly refers to equity shares "held as on the Record Date (as defined under the Scheme)", indicating that the date will be determined as part of the Scheme process.
As per Annexure-A, the actual quantum of bonus NCRPS and the utilisation of general reserves and / or retained earnings will be determined based on the total outstanding equity share capital of the Company as on the Record Date.
Timetable and approvals
The board’s outcome letter on page 1 notes that the Scheme is subject to approvals from:
- Stock Exchanges,
- The jurisdictional National Company Law Tribunal ("NCLT"), and
- Shareholders and creditors (as applicable) of the Company, along with other statutory, regulatory and customary approvals.
Annexure-A further clarifies that:
- The date of allotment of the bonus NCRPS will be after obtaining the approval of the NCLT, pursuant to the Scheme.
- The bonus NCRPS will be allotted to the shareholders of the Company as on the Record Date after obtaining the approval of the NCLT, pursuant to the Scheme.
No specific calendar dates for NCLT hearings, shareholder meetings, allotment, credit of securities or listing commencement are provided in the filing.
Capital structure impact (as per Annexure – A1)
Annexure – A1 in the filing sets out the share capital before and after the proposed bonus issue of NCRPS, based on figures as on November 20, 2026:
- Current authorised share capital:
- 2,00,00,000 Equity Shares of Rs.10/- each, totalling Rs.20,00,00,000.
- Current issued, subscribed and paid-up capital:
- 1,41,30,333 Equity Shares of Rs.10/- each, totalling Rs.14,13,03,330.
Post bonus issue (based on November 20, 2026 figures):
- Authorised share capital:
- 2,00,00,000 Equity Shares of Rs.10/- each – Rs.20,00,00,000.
- 7,30,00,000 Non-Convertible Redeemable Preference Shares of Rs.100/- each – Rs.7,30,00,00,000.
- Total authorised share capital – Rs.7,50,00,00,000.
- Issued, subscribed and paid-up capital:
- 1,41,30,333 Equity Shares of Rs.10/- each – Rs.14,13,03,330.
- 7,06,51,665 Non-Convertible Redeemable Preference Shares of Rs.100/- each – Rs.7,06,51,66,500.
- Total issued, subscribed and paid-up capital – Rs.7,20,64,69,830.
The company states in Annexure-A that there will not be any change in equity shares pursuant to the issuance of NCRPS by way of bonus under the Scheme.
Company’s stated rationale
In Annexure-A, the company explains that the issuance of NCRPS by way of bonus is proposed under the Scheme by utilizing general reserves and / or retained earnings of the Company. The redemption of the NCRPS is proposed to be out of the general reserves and / or retained profits of the Company.
Background
- TTK Healthcare Ltd is classified under Diversified.
- The company’s market capitalisation was about Rs 1,478.00 cr as of 19 Nov 2026.
- For Q2 FY27 (quarter ended 30 Sep 2026), standalone revenue was Rs 233.38 cr against Rs 203.57 cr a year earlier, and PAT was Rs 222.97 cr against Rs 20.39 cr a year earlier.
- Promoter holding was 74.57% at the end of Sep 2026, against 74.57% a year earlier.
- On 16 Nov 2026, the company filed a Board Meeting Intimation, and on 30 Oct 2026 it filed an Outcome Of Board Meeting.
Get TTK Healthcare Ltd-$'s next bonus issue filing the moment it lands
A bonus issue plays out over several exchange filings: the record date, the allotment, the credit of shares. Pro shows each one in your feed as soon as the exchange publishes it, with our summary. A free account sees it an hourback for a day.
- We'll start you off following TTKHLTCARE.
- 14 days free, no card. After that you keep a free account.
Get every filing that moves a stock
One email before the open, with the day's filings that actually shifted a price — the number, the source document and what the market did with it. Free, and you can unsubscribe from any issue.
Cruxal publishes market coverage for information only. Nothing here is investment advice.